BYSI - BeyondSpring: Improving Neulasta's Efficacy And Safety In Chemotherapy-Induced Neutropenia
BeyondSpring (BYSI) is a China-originated undercovered stock in late clinical stage for its lead drug candidate plinabulin in chemotherapy-induced neutropenia ((CIN)). CIN is a common side effect in chemotherapy-treated cancer patients. Chemotherapy destroys white blood cells, specifically neutrophils, making patients susceptible to infections. In these patients, even ordinary infections can become fatal and they have absolutely no defense against serious infections. Such Grade 4, severe neutropenia where patients have an abnormally low neutrophil count is a dangerous side effect of chemotherapy treatment. Existing therapies like G-CSF (Neulasta) often do not work, with patients